TG Therapeutics Highlights BRIUMVI Efficacy in Multiple Sclerosis Data Presentations
Event summary
- TG Therapeutics will present four data sets on BRIUMVI at the 2026 CMSC Annual Meeting, including an oral presentation on patient-reported outcomes from the Phase 4 ENABLE study.
- Real-world data showed 99.4% of patients transitioning to BRIUMVI from prior anti-CD20 therapies remained relapse-free with a low annualized relapse rate of 0.011.
- The presentations will cover infusion tolerability, breast milk concentration, and disease control in relapsing multiple sclerosis (RMS).
- BRIUMVI is a novel monoclonal antibody targeting CD20-expressing B-cells, approved for RMS in the U.S. and several other countries.
The big picture
TG Therapeutics' data presentations at the 2026 CMSC Annual Meeting underscore BRIUMVI's role in the relapsing multiple sclerosis (RMS) treatment landscape. The focus on patient-reported outcomes and real-world efficacy data aligns with broader industry trends emphasizing quality-of-life metrics and real-world evidence in therapeutic evaluations. With nearly 1 million RMS patients in the U.S., BRIUMVI's ability to demonstrate durable improvements in treatment satisfaction and disease control positions it as a key competitor in this growing market.
What we're watching
- Clinical Differentiation
- Whether BRIUMVI's differentiated clinical profile can sustain market share against established RMS treatments.
- Regulatory Dynamics
- The pace at which TG Therapeutics expands BRIUMVI's approvals beyond the U.S. into other key markets.
- Commercial Execution
- How TG Therapeutics scales its commercial infrastructure to meet demand for BRIUMVI in the RMS market.
Related topics